Industry
Ananda Pharma Doses First Patient in NIHR-Backed CIPN Trial
The study is evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN).
Industry
The study is evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN).
Science
News Editor ·
Comment
Sponsored features editor ·
News
Sarah Sinclair ·
Journalism built on science, not speculation.
Upcoming Symposiums
Evidence-led education for clinicians, industry and patient advocates — across Europe.
See all events4 November 2026
Frankfurt · Mainhaus
26 November 2026
London · Conway Hall
Germany has voted to ban medical cannabis flower from its statutory health insurance scheme.
Inhaled cannabis was associated with ‘large, sustained, and statistically robust improvements’ in pain and disability.
Europe’s dedicated medical cannabis education series for clinicians and industry professionals announces two autumn events — 4 November at Mainhaus, Frankfurt, and 26 November at Conway Hall, London
Science & Evidence — Spotlight
We read the studies so you don’t have to — separating robust findings from headlines, with the methods and caveats laid bare.
Explore the research
Plain-language guides to conditions, cannabinoids and what the evidence actually says.
Explore patient guidesRegulatory change, clinical evidence and the patient perspective for prescribers and pharmacists.
Enter the clinical hubDirectory
Browse verified UK medical cannabis clinics and pharmacies — online and in person.
Upcoming Symposiums
Evidence-led education for clinicians, industry and patient advocates — across Europe.
See all events4 November 2026
Frankfurt · Mainhaus
26 November 2026
London · Conway Hall